[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide aden

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE), the glob

The launch expands access to Tru Niagen through one of the country’s largest digital retail platform

Niagen Bioscience (NASDAQ:NAGE) widens FY2026 sales outlook from $138.982 million-$145.299 million t

Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.01 per share which missed the anal

New epigenetic findings show Niagen NR reduces muscle biological aging and supports healthy muscle f

NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide ri

https://www.sec.gov/Archives/edgar/data/1386570/000121390026077234/ea0297322-424b5_niagen.htm

NB4168, a patented therapeutic candidate designed to have significantly increased bioavailability an

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Niagen Bioscience (NASDAQ:NAGE) with

U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ:

Niagen Bioscience reaffirms 2026 sales outlook after first-quarter revenue and profit rose alongside

2026 Full Year OutlookNet sales: Increasing between 10-15% year-over-year excluding 2025 net sales a

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleoti

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleoti

U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting ear

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleot

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleot

Niagen Bioscience estimates the program has generated more than $200 million in third-party research

Shares of Veeva Systems Inc (NYSE: VEEV) gained 11.3% in pre-market trading on upbeat Q4 results and

Niagen Bioscience Inc. surged in after-hours trading after reporting record 2025 results, while main

NAD+ company Niagen Bioscience doubles profits in 2025, eyes acquisitions and new markets as the lon

2026 Outlook

Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.03 per share which beat the analys

Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.05 per share which beat the analys

Divestiture streamlines operations and advances the Company's strategy to fully exit non-core ac

This acquisition establishes Niagen Bioscience as the sole owner of the most comprehensive and defen

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleot

Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and

Niagen Bioscience (NASDAQ:NAGE) affirms FY2025 sales outlook from $124.496 million-$129.476 million

Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.05 per share which beat the analys

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleoti

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Niagen Bioscience (NASDAQ:NAGE) with

Niagen Bioscience (NASDAQ:NAGE) raises FY2025 sales outlook from $119.516 million-$124.496 million t

Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.04 per share which beat the analys

Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nico

Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and

Results demonstrated that nicotinamide riboside (NR) significantly elevated NAD+ levels and improved

Roth Capital analyst Sean McGowan maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and raises